NEW STUDY: PROPOSALS IN CANADA-EU TRADE NEGOTIATIONS WOULD ADD $1.2 BILLION ANNUALLY TO ONTARIO'S PRESCRIPTION DRUG BILL

Proposals would wipe out savings achieved through Ontario's recent drug plan reforms

TORONTO, Feb. 7 /CNW/ - Changes to Canada's drug patent system proposed by the European Union (EU) would add approximately $1.2-billion annually to Ontario's prescription drug bill according to a new study by two of Canada's top academics on pharmaceutical policy.

The study, The Canada-European Union Comprehensive Economic & Trade Agreement: An Economic Impact Assessment of Proposed Pharmaceutical Intellectual Property Provisions, was authored by Professor Aidan Hollis of the Department of Economics at the University of Calgary and Paul Grootendorst from the University of Toronto's Faculty of Pharmacy. The study was commissioned and released today by the Canadian Generic Pharmaceutical Association (CGPA).

Canada and the EU are currently in negotiations for a comprehensive economic and trade agreement (CETA), which International Trade Minister Peter Van Loan hopes to conclude before the end of 2011. As part of these negotiations, the EU has tabled proposals that would considerably lengthen the period of market exclusivity for brand-name drugs in Canada and, according to the authors of the study released today, would provide "the most extensive structural protection for innovative drugs of any country in the world."

The study's key finding is that Canadian payers, such as the federal government, provincial governments, businesses and patients "would face substantially higher drug costs as exclusivity is extended on top-selling prescription drugs, with the annual increase in costs likely to be approximately $2.8-billion per year." Of that $2.8-billion in additional annual costs, approximately $1.2-billion would be borne by the Ontario government, Ontario employers that sponsor drug plans for their employees and Ontario patients.

In June 2010, the Government of Ontario passed reforms to lower costs for the government's drug benefit plan as well as employer-sponsored drug plans and those Ontarians that pay for their prescriptions out-of-pocket.

"Today's study shows that the savings achieved for both public and private drug plans through the Ontario government's recent reforms would be wiped out if the EU's proposals are implemented," said Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA). "Those savings were supposed to help preserve and enhance Ontario's health-care system, not increase profits for brand-name drug companies."

Importantly, the study reveals that the EU's proposed changes would not lead to a substantial increase in investment by brand-name drug companies in Canada. "The purpose of exclusivity rights granted to innovators is to create an incentive for research and development investments into new drugs. However, the amount of additional investment in pharmaceutical innovation that would result from the EU's proposed pharmaceutical IP provisions would be a small fraction of the additional costs to Canadians."

Keon pointed out that pharmaceuticals are one of the EU's top exports to Canada, comprising 15.6 percent of total exports with a value of more than $5 billion annually.

"The generic pharmaceutical industry supports the Government of Canada's efforts to increase trade with other jurisdictions," said Keon. "The pharmaceutical intellectual property proposals tabled by the EU, however, will not eliminate trade barriers, as pharmaceutical products from the EU already have unfettered access to the Canadian market. These proposals will simply increase profits for brand-name drug companies at the expense of Canada's health-care system."

To view the full report, please visit www.canadiangenerics.ca

About the Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) represents Canada's generic pharmaceutical industry. The industry plays an important role in controlling health-care costs in Canada. Generic drugs are dispensed to fill 57 per cent of all prescriptions but account for only 25 per cent of the $23-billion Canadians spend annually on prescription medicines.

SOURCE Canadian Generic Pharmaceutical Association

For further information:

Jeff Connell
Vice President, Corporate Affairs
Canadian Generic Pharmaceutical Association (CGPA)
Tel: (416) 223-2333
Mobile: (647) 274-3379
Email: jeff@canadiangenerics.ca
Website: www.canadiangenerics.ca


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890